2026-04-17T03:47:20Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/71002025-10-24T10:29:19Zcom_2072_378070com_2072_378040col_2072_378092

Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19 Buxeda, Anna Arias-Cabrales, Carlos Pérez-Sáez, María José Cacho, Judit Cabello Pelegrin, Sheila Moreso Mateos, Francesc Melilli, Edoardo Institut Català de la Salut [Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ] Department of Nephrology, Hospital del Mar, Institute Mar for Medical Research (IMIM), Red de Investigación Renal (REDinREN) (RD16/0009/0013), Barcelona, Spain. [Cacho J] Department of Nephrology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Cabello Pelegrin S] Department of Nephrology, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Melilli E] Department of Nephrology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain. [Moreso F] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus COVID-19 (Malaltia) - Tractament Insuficiència renal aguda Avaluació de resultats (Assistència sanitària) DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections Other subheadings::Other subheadings::Other subheadings::/drug therapy DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Acute Kidney Injury ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::lesión renal aguda TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Trasplantament de ronyó; Remdesivir Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Trasplante de riñón; Remdesivir Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Kidney transplantation; Remdesivir Introduction Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. Methods We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Results Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. Conclusion In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy. 2022-03-01T07:27:27Z 2022-03-01T07:27:27Z 2021-09 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ, Cacho J, Cabello Pelegrin S, Melilli E, et al. Use and safety of remdesivir in kidney transplant recipients with COVID-19. Kidney Int Reports. 2021 Sep;6(9):2305–2315. 2468-0249 https://hdl.handle.net/11351/7100 10.1016/j.ekir.2021.06.023 34250317 000696709200009 http://hdl.handle.net/11351/7100 eng Kidney International Reports;6(9) https://doi.org/10.1016/j.ekir.2021.06.023 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf application/pdf Elsevier Scientia